Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novavax, VaxInnate Receive BARDA Funds For Recombinant Flu Vaccine Development

This article was originally published in The Pink Sheet Daily

Executive Summary

New processes would speed vaccine production and could improve on efficacy.

You may also be interested in...

Deals Of The Week: Express Scripts/Walgreens, Par/TPG, Amicus/GSK

Following the clinical trial failure of cancer candidate saridegib, Infinity takes back partnered assets from Purdue and plans to go it alone in the PI3K space.

Cell-Based Vaccine Development Gives Protein Sciences The Chills; Challenges Include Getting Advisory Committees To Accept FDA Decisions

Developing a new class of medical products takes creativity and perseverance by both sponsors and regulators, but as Protein Sciences' experience shows, bringing advisory committees up to speed on novel technologies can be just as important and challenging

Chick Eggs Cannot Yield Enough Vaccine For Pandemic: NYAS Swine Flu Mtg.

If preparation for a possible pandemic is ever going to be sufficient, drug makers need to push for FDA approval of adjuvants and novel technologies in which influenza vaccines can be created, according to a panel of experts


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts